Brief: Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation
09/06/2025 13:13
June 9 (Reuters) - Sino Biopharmaceutical 1177.HK: TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" APPROVED BY CENTER FOR DRUG EVALUATION BY NMPA CHINA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit